Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Bortezomib Consolidation Trial
- Status
- COMPLETED
- Phase
- PHASE2
Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)
- Status
- COMPLETED
- Phase
- PHASE1
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE2
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE3
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
- Status
- TERMINATED
- Phase
- PHASE2
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
- Status
- TERMINATED
- Phase
- PHASE2
Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL
- Status
- UNKNOWN
- Phase
- PHASE3
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
- Status
- UNKNOWN
- Phase
- PHASE1
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2